Filing Flows › Adma Biologics (ADMA) › Net income
Adma Biologics (ADMA) net income by quarter
Adma Biologics' net income was $49.9M in Q3 2026 (third quarter 2026), +32% from Q2 2026. Over the last 7 quarters it ranged from $26.9M (Q1 2025) to $49.9M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $49.9M | +32% | +37% |
| Q2 2026 | $37.8M | -17% | +11% |
| Q1 2026 | $45.3M | -8% | +68% |
| Q4 2025 | $49.4M | +36% | — |
| Q3 2025 | $36.4M | +6% | — |
| Q2 2025 | $34.2M | +27% | — |
| Q1 2025 | $26.9M | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' net income?
Adma Biologics' net income was $49.9M in Q3 2026 (third quarter 2026), +32% from Q2 2026.
How has Adma Biologics' net income changed?
Over the last 7 quarters it ranged from $26.9M (Q1 2025) to $49.9M (Q3 2026).